UCSD
The preprint raised concerns about the findings of a 2020 cancer microbiome study that spurred the development of a microbiome-based liquid biopsy test for cancer.
BillionToOne, UCSD Partner to Assess New Liquid Biopsy Assays in Lung Cancer
Investigators are evaluating the firm's tumor profiling and treatment response monitoring assays and expect initial results in a few months.
FDA Grants EUAs for UCSD SARS-CoV-2 Test, D.C. Health Specimen Collection Kit
The test was developed by the UCSD BCG Expedited Covid Identification Environment Lab, while the collection kit is used with a Labcorp COVID-19 test.
Personalis, UCSD Cancer Center Ink Clinical Genomic Testing, Research Partnership
The company will provide comprehensive genomic tumor testing and will work with UCSD researchers to develop new biomarkers and test its new liquid biopsy assay.
FDA Grants Emergency Use Authorization for UCSD Molecular COVID-19 Test
The PCR-based test was developed by the UCSD BCG Expedited Covid Identification Environment (EXCITE) Lab.